Search

Your search keyword '"MESH: Evidence-Based Medicine"' showing total 22 results
Start Over Descriptor "MESH: Evidence-Based Medicine" Search Limiters Full Text
22 results on '"MESH: Evidence-Based Medicine"'

1. A framework for an evidence-based gene list relevant to autism spectrum disorder

Author

Peter Szatmari, Mayada Elsabbagh, Wendy K. Chung, Helen V. Firth, Ny Hoang, Jacques L. Michaud, Catalina Betancur, Janet A. Buchanan, Jennifer L. Howe, Jacob A. S. Vorstman, Louise Gallagher, Christian P. Schaaf, Edwin H. Cook, Joseph D. Buxbaum, Kira A. Dies, Olivia Rennie, Stephen W. Scherer, Raphael Bernier, Jeremy R. Parr, Ryan K. C. Yuen, Patrick Bolton, Thomas W. Frazier, Christian R. Marshall, Chun-An Chen, David Skuse, Betancur, Catalina, Institute of Human Genetics [Heidelberg, Germany], Universität Heidelberg [Heidelberg], Baylor College of Medicine (BCM), Baylor University, Texas Children's Hospital [Houston, USA], Neuroscience Paris Seine (NPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), The Hospital for sick children [Toronto] (SickKids), University of Toronto, Newcastle University [Newcastle], University College of London [London] (UCL), Trinity College Dublin, University of Washington [Seattle], Children's Autism Center [Seattle, WA, USA], Icahn School of Medicine at Mount Sinai [New York] (MSSM), Department of Neurology, Children's Hospital [Boston], Boston Children's Hospital, Montreal Neurological Institute and Hospital, McGill University = Université McGill [Montréal, Canada], Cambridge University Hospitals - NHS (CUH), University of Cambridge [UK] (CAM), The Wellcome Trust Sanger Institute [Cambridge], Autism Speaks [Cleveland, OH, USA], Centre de recherche du CHU Sainte-Justine / Research Center of the Sainte-Justine University Hospital [Montreal, Canada], Université de Montréal (UdeM)-CHU Sainte Justine [Montréal], Centre for Addiction and Mental Health [Toronto] (CAMH), Columbia University Medical Center (CUMC), Columbia University [New York], Institute of Psychiatry, Psychology & Neuroscience, King's College London, King‘s College London, University of Illinois [Chicago] (UIC), University of Illinois System, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa [Ottawa], Génétique de l'autisme = Genetics of Autism (NPS-01), Neurosciences Paris Seine (NPS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche du CHU Sainte-Justine [Montreal], and CHU Sainte Justine [Montréal]-Université de Montréal (UdeM)

Subjects
Evidence-based practice, Research groups, Autism Spectrum Disorder, MEDLINE, MESH: Cognition, Computational biology, [SDV.GEN] Life Sciences [q-bio]/Genetics, Biology, behavioral disciplines and activities, MESH: Intellectual Disability, 03 medical and health sciences, MESH: Brain, Cognition, 0302 clinical medicine, Intellectual Disability, mental disorders, Genetics, medicine, Humans, Molecular Biology, Genetic Association Studies, Genetics (clinical), 030304 developmental biology, MESH: Genetic Association Studies, MESH: Autism Spectrum Disorder, 0303 health sciences, [SDV.GEN]Life Sciences [q-bio]/Genetics, Evidence-Based Medicine, MESH: Humans, Extramural, Brain, Evidence-based medicine, medicine.disease, Clinical Practice, Autism spectrum disorder, Gene list, 030217 neurology & neurosurgery, MESH: Evidence-Based Medicine
Abstract

International audience; Autism spectrum disorder (ASD) is often grouped with other brain-related phenotypes into a broader category of neurodevelopmental disorders (NDDs). In clinical practice, providers need to decide which genes to test in individuals with ASD phenotypes, which requires an understanding of the level of evidence for individual NDD genes that supports an association with ASD. Consensus is currently lacking about which NDD genes have sufficient evidence to support a relationship to ASD. Estimates of the number of genes relevant to ASD differ greatly among research groups and clinical sequencing panels, varying from a few to several hundred. This Roadmap discusses important considerations necessary to provide an evidence-based framework for the curation of NDD genes based on the level of information supporting a clinically relevant relationship between a given gene and ASD.

Published
2020
Full Text
View/download PDF

2. Glucocorticoids in rheumatoid arthritis: current status and future studies

Author

C. Hua, Bernard Combe, Frank Buttgereit, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Institut de Génétique Moléculaire de Montpellier (IGMM), and Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)

Subjects
MESH: Antirheumatic Agents, Future studies, lcsh:Medicine, corticosteroids, Arthritis, Rheumatoid, 0302 clinical medicine, MESH: Practice Guidelines as Topic, Daily practice, Immunology and Allergy, 030212 general & internal medicine, MESH: Treatment Outcome, Randomized Controlled Trials as Topic, MESH: Arthritis, Rheumatoid, Evidence-Based Medicine, treatment, 3. Good health, Treatment Outcome, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatoid arthritis, Antirheumatic Agents, Practice Guidelines as Topic, Drug Therapy, Combination, Early arthritis, medicine.medical_specialty, Immunology, Rheumatoid Arthritis, MESH: Drug Administration Schedule, Drug Administration Schedule, 03 medical and health sciences, Rheumatology, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Internal medicine, medicine, Humans, Intensive care medicine, Glucocorticoids, 030203 arthritis & rheumatology, MESH: Humans, business.industry, lcsh:R, medicine.disease, MESH: Drug Therapy, Combination, MESH: Randomized Controlled Trials as Topic, Relative risk, Antirheumatic drugs, business, MESH: Glucocorticoids, Rheumatism, MESH: Evidence-Based Medicine
Abstract

International audience; Since their first use for treating rheumatoid arthritis (RA) in the late 1940s, glucocorticoids (GCs) have been representing a substantial part of the therapeutic arsenal for RA. However, even if GCs are still widely prescribed drugs, their toxicity is discussed controversially, so obtaining consensus on their use in RA is difficult. Hence, the most recent European League Against Rheumatism and American College of Rheumatology recommendations on early arthritis and RA management advocate the use of GCs as adjunct treatment to conventional synthetic disease-modifying antirheumatic drugs, at the lowest dose possible and for the shortest time possible. However, the recommendations remain relatively vague on dose regimens and routes of administration. Here, we describe literature data on which the current recommendations are based as well as data from recent trials published since the drafting of the guidelines. Moreover, we make proposals for daily practice and provide suggestions for studies that could help clarifying the place of GCs in RA management. Indeed, numerous items, including the benefit/risk ratio of low-dose and very low-dose GCs and optimal duration of GCs as bridging therapy, remain on the research agenda, and future studies are needed to guide the next recommendations for RA.

Published
2020
Full Text
View/download PDF

3. An ontological foundation for ocular phenotypes and rare eye diseases

Author

Sergouniotis, Panagiotis I., Maxime, Emmanuel, Leroux, Dorothée, Olry, Annie, Thompson, Rachel, Rath, Ana, Robinson, Peter N., Dollfus, Hélèneashworth, Jl, Audo, I, Balciuniene, Vj, Banin, E, Black, Gc, Böhringer, D, Boon, Cjf, Bremond-Gignac, D, Calvas, P, Castela, G, Dagnelie, G, Dollfus, H, Downes, Sm, Fasolo, A, Fasser, C, Gelzinis, A, Goetz, K, Hamann, S, Héon, E, Iarossi, G, Kawasaki, A, Keegan, D, Kessel, L, Khan, K, Klett, A, Köhler, S, Leroux, D, Leroy, Bp, Lisch, W, Liskova, P, Lorenz, B, Maggi, R, Maxime, E, Meunier, I, Mohand-Said, S, Nowomiejska, K, Perdomo, Y, Petzold, A, Preising, M, Robinson, Pn, Scholl, Hpn, Sergouniotis, Pi, Sodi, A, Stingl, K, Studer, F, Suppiej, A, Thompson, R, Touitou, V, Traboulsi, E, Trumpaitis, J, Tuft, Sj, Vaclavik, V, Valeina, S, Van Cauwenbergh, C, Verloes, A, Vighetto, A, Wheeler, R, Wheeler-Schilling, T, Yu-Wai-Man, P, Zobor, D, Zrenner, E., Sergouniotis, Panagiotis I [0000-0003-0986-4123], Apollo - University of Cambridge Repository, University of Manchester [Manchester], Plateforme d'information et de services pour les maladies rares et les médicaments orphelins (Orphanet), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Broussais-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO) et Service de Génétique Médicale, Hôpitaux Universitaires de Strasbourg, Newcastle University [Newcastle], The Jackson Laboratory for Genomic Medicine, Laboratoire de Génétique Médicale (LGM), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), and European Project: 0305444(2003)

Subjects
0301 basic medicine, Eye Diseases, Computer science, Evidence-based precision medicine, Rare eye disease, Human phenotype ontology, Orphanet rare disease ontology, lcsh:Medicine, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, 030105 genetics & heredity, Ontology (information science), Terminology, NO, Open Biomedical Ontologies, MESH: Eye Diseases / classificationHumans Precision Medicine / methods* Rare Diseases / classification, 03 medical and health sciences, 0302 clinical medicine, Rare Diseases, Human Phenotype Ontology, Eye Diseases/classification, Humans, Pharmacology (medical), Precision Medicine, Letter to the Editor, MESH: Humans Precision Medicine / methods, Genetics (clinical), Information exchange, Evidence-Based Medicine, Orphanet rare disease ontology, Rare Diseases/classification, MESH: Computational Biology / methods, lcsh:R, Computational Biology, Human phenotype ontology, Biological Ontologies, Precision Medicine/methods, General Medicine, Evidence-based medicine, Rare eye disease, Computational Biology/methods, Data science, MESH: Rare Diseases / classification, 3. Good health, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Evidence-based precision medicine, Eye disorder, MESH: Biological Ontologies, MESH: Evidence-Based Medicine, 030217 neurology & neurosurgery
Abstract

Background The optical accessibility of the eye and technological advances in ophthalmic diagnostics have put ophthalmology at the forefront of data-driven medicine. The focus of this study is rare eye disorders, a group of conditions whose clinical heterogeneity and geographic dispersion make data-driven, evidence-based practice particularly challenging. Inter-institutional collaboration and information sharing is crucial but the lack of standardised terminology poses an important barrier. Ontologies are computational tools that include sets of vocabulary terms arranged in hierarchical structures. They can be used to provide robust terminology standards and to enhance data interoperability. Here, we discuss the development of the ophthalmology-related component of two well-established biomedical ontologies, the Human Phenotype Ontology (HPO; includes signs, symptoms and investigation findings) and the Orphanet Rare Disease Ontology (ORDO; includes rare disease nomenclature/nosology). Methods A variety of approaches were used including automated matching to existing resources and extensive manual curation. To achieve the latter, a study group including clinicians, patient representatives and ontology developers from 17 countries was formed. A broad range of terms was discussed and validated during a dedicated workshop attended by 60 members of the group. Results A comprehensive, structured and well-defined set of terms has been agreed on including 1106 terms relating to ocular phenotypes (HPO) and 1202 terms relating to rare eye disease nomenclature (ORDO). These terms and their relevant annotations can be accessed in http://www.human-phenotype-ontology.org/ and http://www.orpha.net/; comments, corrections, suggestions and requests for new terms can be made through these websites. This is an ongoing, community-driven endeavour and both HPO and ORDO are regularly updated. Conclusions To our knowledge, this is the first effort of such scale to provide terminology standards for the rare eye disease community. We hope that this work will not only improve coding and standardise information exchange in clinical care and research, but also it will catalyse the transition to an evidence-based precision ophthalmology paradigm. Electronic supplementary material The online version of this article (10.1186/s13023-018-0980-6) contains supplementary material, which is available to authorized users.

Published
2019
Full Text
View/download PDF

4. Helping GPs to extrapolate guideline recommendations to patients for whom there are no explicit recommendations, through the visualization of drug properties. The example of AntibioHelp® in bacterial diseases

Author

Mélanie Courtine, Hector Falcoff, Frédéric Mechaï, Ronni Madar, Antoine De Beco, Jean-Baptiste Lamy, Rosy Tsopra, Karima Sedki, Lamy, Jean-Baptiste, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Société de Formation Thérapeutique du Généraliste (SFTG), Université Paris Descartes - Paris 5 (UPD5), UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord

Subjects
Male, 020205 medical informatics, 02 engineering and technology, MESH: Medication Errors, infectious diseases, antibiotics, [INFO.INFO-AI]Computer Science [cs]/Artificial Intelligence [cs.AI], User-Computer Interface, 0302 clinical medicine, MESH: Practice Guidelines as Topic, 0202 electrical engineering, electronic engineering, information engineering, Medicine, Medication Errors, 030212 general & internal medicine, Practice Patterns, Physicians', MESH: Aged, Cross-Over Studies, Evidence-Based Medicine, MESH: Middle Aged, Bacterial Infections, Middle Aged, 3. Good health, Anti-Bacterial Agents, MESH: General Practitioners, Clinical Practice, clinical decision support system, Practice Guidelines as Topic, Global Positioning System, Data Display, Female, clinical practice guidelines, Adult, [INFO.INFO-AI] Computer Science [cs]/Artificial Intelligence [cs.AI], medicine.medical_specialty, Attitude of Health Personnel, MESH: Bacterial Infections, MESH: Attitude of Health Personnel, Health Informatics, Primary care, Research and Applications, Clinical decision support system, MESH: Cross-Over Studies, 03 medical and health sciences, primary care, General Practitioners, MESH: Anti-Bacterial Agents, Humans, Medical prescription, Intensive care medicine, visualization, Aged, MESH: User-Computer Interface, MESH: Humans, business.industry, MESH: Adult, Guideline, Decision Support Systems, Clinical, MESH: Male, Visualization, Interaction time, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Practice Patterns, Physicians', MESH: Decision Support Systems, Clinical, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, MESH: Data Display, MESH: Evidence-Based Medicine
Abstract

Introduction Clinical decision support systems (CDSS) implementing clinical practice guidelines (CPGs) have 2 main limitations: they target only patients for whom CPGs provide explicit recommendations, and their rationale may be difficult to understand. These 2 limitations result in poor CDSS adoption. We designed AntibioHelp® as a CDSS for antibiotic treatment. It displays the recommended and nonrecommended antibiotics, together with their properties, weighted by degree of importance as outlined in the CPGs. The aim of this study was to determine whether AntibioHelp® could increase the confidence of general practitioners (GPs) in CPG recommendations and help them to extrapolate guidelines to patients for whom CPGs provide no explicit recommendations. Materials and Methods We carried out a 2-stage crossover study in which GPs responded to clinical cases using CPG recommendations either alone or with explanations displayed through AntibioHelp®. We compared error rates, confidence levels, and response times. Results We included 64 GPs. When no explicit recommendation existed for a particular situation, AntibioHelp® significantly decreased the error rate (−41%, P value = 6x10−13), and significantly increased GP confidence (+8%, P value = .02). This CDSS was considered to be usable by GPs (SUS score = 64), despite a longer interaction time (+9–22 seconds). By contrast, AntibioHelp® had no significant effect if there was an explicit recommendation. Discussion/Conclusion The visualization of weighted antibiotic properties helps GPs to extrapolate recommendations to patients for whom CPGs provide no explicit recommendations. It also increases GP confidence in their prescriptions for these patients. Further evaluations are required to determine the impact of AntibioHelp® on antibiotic prescriptions in real clinical practice.

Published
2019
Full Text
View/download PDF

5. Characteristics and Outcome of Patients Hospitalised for Lower Extremity Peripheral Artery Disease in France: The COPART Registry

Author

A. Bura, Philippe Lacroix, Victor Aboyans, C. Dentans, Jean Pierre Cambou, Joël Constans, Neuroépidémiologie Tropicale et Comparée (NETEC), Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Université de Limoges (UNILIM), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], and CHU Limoges

Subjects
Male, MESH: Chi-Square Distribution, MESH: Gangrene, medicine.medical_treatment, MESH: Lower Extremity, MESH: Risk Assessment, MESH: Length of Stay, MESH: Intermittent Claudication, Hospitals, University, 0302 clinical medicine, Hospital Mortality, Prospective Studies, MESH: Treatment Outcome, Aged, 80 and over, Peripheral Vascular Diseases, Evidence-Based Medicine, MESH: Middle Aged, 3. Good health, Outcome and Process Assessment, Health Care, Lower Extremity, Bypass surgery, Cardiovascular Diseases, MESH: Guideline Adherence, Guideline Adherence, MESH: Cardiovascular Agents, Cardiology and Cardiovascular Medicine, Vascular Surgical Procedures, MESH: Leg Ulcer, Registry, medicine.medical_specialty, Risk Assessment, Gangrene, 03 medical and health sciences, Angioplasty, Humans, MESH: Amputation, MESH: Hospital Mortality, MESH: Kaplan-Meier Estimate, Aged, Chi-Square Distribution, MESH: Humans, MESH: Peripheral Vascular Diseases, MESH: Cardiovascular Diseases, Cardiovascular Agents, Study design, Intermittent Claudication, Length of Stay, medicine.disease, Surgery, MESH: Ischemia, MESH: Female, Chi-squared distribution, Angioplasty, Balloon, Acute limb ischaemia, Time Factors, MESH: Registries, Kaplan-Meier Estimate, MESH: Hospitalization, 030204 cardiovascular system & hematology, MESH: Proportional Hazards Models, MESH: Aged, 80 and over, MESH: Practice Guidelines as Topic, Ischemia, Risk Factors, MESH: Risk Factors, Registries, 030212 general & internal medicine, Prospective cohort study, MESH: Aged, Medicine(all), Mortality rate, Leg Ulcer, Middle Aged, Hospitalization, Treatment Outcome, Practice Guidelines as Topic, Female, France, medicine.symptom, MESH: Angioplasty, Balloon, MESH: Outcome and Process Assessment (Health Care), Outcomes, Amputation, Surgical, Internal medicine, medicine, MESH: Vascular Surgical Procedures, Proportional Hazards Models, MESH: Hospitals, University, Peripheral artery disease, business.industry, MESH: Time Factors, MESH: Male, MESH: Prospective Studies, Intermittent claudication, MESH: France, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Evidence-Based Medicine
Abstract

International audience; OBJECTIVES: To assess the current 'real-world' management of hospitalised patients with lower-extremity peripheral artery disease (LE-PAD) and to assess the 1-year outcome. DESIGN, MATERIALS AND METHODS: The prospective and multicentre registry COhorte des Patients ARTériopathes (COPART) recruited consecutive patients from the departments of vascular medicine of three academic hospitals in Southwestern France. RESULTS: Among the 940 patients, 27.4% had intermittent claudication (IC), 9.3% ischaemic rest pain, 54.3% ulceration or gangrene and 9.3% acute limb ischaemia (ALI). Patients with IC were younger and more likely to be men, with a history of smoking (89.5%) and chronic obstructive pulmonary disease (17%). Among those with IC, 8.9% had bypass surgery and 41.5% were treated with percutaneous angioplasty. Those with tissue loss had higher rates of cardiovascular disease (CVD) risk factors and co-morbidities. At entry to the study, the level of control of the CVD risk factors was poor. The 1-year mortality rate was of 5.7% in patients with IC, 23.1% in patients with ischaemic rest pain, 28.7% in patients with tissue loss and 23% in those with ALI. Compliance with evidence-based medicine and pharmacological treatment was sub-optimal. CONCLUSION: This registry underscores the differences in patient profiles in the daily clinical setting, compared to those enrolled in several trials.

Published
2010
Full Text
View/download PDF

6. Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project

Author

Michaela A, Stoffer, Josef S, Smolen, Anthony, Woolf, Ales, Ambrozic, Florian, Berghea, Annelies, Boonen, Ailsa, Bosworth, Loreto, Carmona, Maxime, Dougados, Maarten, de Wit, Josephine, Erwin, Veronika, Fialka-Moser, Ruxandra, Ionescu, Anne-Maree, Keenan, Estibaliz, Loza, Rikke H, Moe, Rolf, Greiff, Pawel, Olejnik, Ingemar F, Petersson, Anne-Christine, Rat, Blaz, Rozman, Britta, Strömbeck, Lorraine, Tanner, Till, Uhlig, Theodora P M Vliet, Vlieland, Tanja A, Stamm, Medizinische Universität Wien = Medical University of Vienna, Royal Cornwall Hospital, University Medical Centre Ljubljana (UMCL), Universitatea de Medicina si Farmacie Carol Davila = Université de médecine et pharmacie Carol Davila (UMFCD), Maastricht University Medical Center (MUMC), Maastricht University [Maastricht], National Rheumatoid Arthritis Society (NRAS), Instituto de Salud Musculoesqueletica (InMusc), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Reumapatientenbond, NIHR - Leeds Musculoskeletal Biomedical Research Unit (LMBRU), National Institute for Health Research (NIHR), University of Leeds, National Advisory Unit on Rehabilitation in Rheumatology (NKRR ), Rheumatikerförbundet = Swedish Rheumatism Association, Instytut Reumatologii, Lund University [Lund], Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Leiden University Medical Center (LUMC), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), University Medical Centre Ljubljana [Ljubljana, Slovenia] (UMCL), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Maastricht University Medical Centre (MUMC), Interne Geneeskunde, RS: CAPHRI School for Public Health and Primary Care, and RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation

Subjects
Delphi Technique, Delphi method, Psychological intervention, Alternative medicine, Osteoarthritis, GUIDELINES, MESH: Delphi Technique, 0302 clinical medicine, MESH: Osteoarthritis, Multidisciplinary approach, Patient-Centered Care, Immunology and Allergy, Orthopedics and Sports Medicine, computer.programming_language, Evidence-Based Medicine, 030503 health policy & services, Health services research, Standard of Care, Checklist, 3. Good health, Europe, EULAR RECOMMENDATIONS, 0305 other medical science, MESH: Pain Management, medicine.medical_specialty, Immunology, Biomedical Engineering, KNEE OSTEOARTHRITIS, General Biochemistry, Genetics and Molecular Biology, MESH: Patient-Centered Care, Patient perspective, 03 medical and health sciences, Nursing, Rheumatology, ESCISIT, medicine, MANAGEMENT, Humans, Pain Management, QUALITY, MESH: Standard of Care, 030203 arthritis & rheumatology, HIP, MESH: Humans, business.industry, Evidence-based medicine, Clinical and Epidemiological Research, medicine.disease, RHEUMATOID-ARTHRITIS, Family medicine, Physical therapy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, business, computer, Patient centred, Delphi, STANDING-COMMITTEE, MESH: Evidence-Based Medicine, TASK-FORCE
Abstract

ObjectiveThe eumusc.net project is an initiative founded by the European Community and the European League Against Rheumatism. One aim of the project was to facilitate equal standards for musculoskeletal health across Europe. The aim of this work-package was to develop patient-centred and consensus based standards of care (SOC) for osteoarthritis (OA), which should be available in a professional and a patient version.MethodsA systematic review concerning guidelines dealing with OA was conducted. Furthermore, experts in musculoskeletal diseases were contacted to ensure that ‘grey’ literature was not excluded. Documents that fulfilled predefined inclusion/exclusion criteria were included and all interventions for OA were extracted and categorised. Based on this list of interventions, a three round Delphi exercise with an international and multidisciplinary expert panel, including patient research partners, was performed to achieve expert consensus.ResultsSix documents were included and used for further analysis. Out of them, 46 interventions have been extracted and 10 consensus based SOC were formulated. In addition, a patient version, written in a lay-understandable wording and in the format of checklist questions was developed. An example is SOC 5: “People with OA should achieve optimal pain control using pharmacological and non-pharmacological means.” The matching patient-centred checklist question reads: “Do I know how to control pain associated with OA?”ConclusionsThe SOC for OA will be available in the 23 languages of the European Union to enhance unified information to patients and professionals and to further harmonise the treatment/care of OA within Europe.

Published
2015
Full Text
View/download PDF

7. Evidence of Functional Connectivity between Auditory Cortical Areas Revealed by Amplitude Modulation Sound Processing

Author

Marie Guéguin, Gérard Faucon, Catherine Liégeois-Chauvel, Patrick Chauvel, Régine Le Bouquin-Jeannès, Senhadji, Lotfi, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epilepsies, Lesions Cerebrales et Systemes Neuraux de la Cognition, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Auditory Pathways, Planum temporale, Audiology, computer.software_genre, 0302 clinical medicine, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Gyrus, Audio signal processing, 0303 health sciences, Evidence-Based Medicine, Cognitive neuroscience of music, Sulcus, MESH: Evoked Potentials, Auditory, medicine.anatomical_structure, [SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs, MESH: Auditory Pathways, MESH: Epilepsy, Auditory Perception, Evoked Potentials, Auditory, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Psychology, Perceptual Masking, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Adult, Auditory perception, medicine.medical_specialty, [INFO.INFO-TS] Computer Science [cs]/Signal and Image Processing, Cognitive Neuroscience, Auditory area, MESH: Acoustic Stimulation, Auditory cortex, Article, MESH: Auditory Perception, 03 medical and health sciences, Cellular and Molecular Neuroscience, medicine, Humans, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing, 030304 developmental biology, Auditory Cortex, [SDV.IB] Life Sciences [q-bio]/Bioengineering, Epilepsy, MESH: Humans, MESH: Adult, MESH: Male, Acoustic Stimulation, MESH: Perceptual Masking, MESH: Auditory Cortex, MESH: Female, computer, Neuroscience, MESH: Evidence-Based Medicine, 030217 neurology & neurosurgery
Abstract

International audience; The human auditory cortex includes several interconnected areas. A better understanding of the mechanisms involved in auditory cortical functions requires a detailed knowledge of neuronal connectivity between functional cortical regions. In human, it is difficult to track in vivo neuronal connectivity. We investigated the interarea connection in vivo in the auditory cortex using a method of directed coherence (DCOH) applied to depth auditory evoked potentials (AEPs). This paper presents simultaneous AEPs recordings from insular gyrus (IG), primary and secondary cortices (Heschl's gyrus and planum temporale), and associative areas (Brodmann area [BA] 22) with multilead intracerebral electrodes in response to sinusoidal modulated white noises in 4 epileptic patients who underwent invasive monitoring with depth electrodes for epilepsy surgery. DCOH allowed estimation of the causality between 2 signals recorded from different cortical sites. The results showed 1) a predominant auditory stream within the primary auditory cortex from the most medial region to the most lateral one whatever the modulation frequency, 2) unidirectional functional connection from the primary to secondary auditory cortex, 3) a major auditory propagation from the posterior areas to the anterior ones, particularly at 8, 16, and 32 Hz, and 4) a particular role of Heschl's sulcus dispatching information to the different auditory areas. These findings suggest that cortical processing of auditory information is performed in serial and parallel streams. Our data showed that the auditory propagation could not be associated to a unidirectional traveling wave but to a constant interaction between these areas that could reflect the large adaptive and plastic capacities of auditory cortex. The role of the IG is discussed.

Published
2006
Full Text
View/download PDF

8. French Society of Cardiology guidelines for cardiac rehabilitation in adults. [Recommandations de la Société française de cardiologie pour la pratique de la réadaptation cardiaque chez l'adulte.]

Author

Pavy, Bruno, Iliou, Marie-Christine, Vergès-Patois, Bénédicte, Brion, Richard, Monpère, Catherine, Carré, François, Aeberhard, Patrick, Argouach, Claudie, Borgne, Anne, Consoli, Silla, Corone, Sonia, Fischbach, Michel, Fourcade, Laurent, Lecerf, Jean-Michel, Mounier-Vehier, Claire, Paillard, François, Pierre, Bernard, Swynghedauw, Bernard, Theodose, Yves, Thomas, Daniel, Claudot, Frédérique, Cohen-Solal, Alain, Douard, Hervé, Marcadet, Dany, Réadaptation Cardiovasculaire, CHU Loire Vendée Océan, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Service de Médecine légale et de Droit de la Santé, Faculté de Médecine [Nancy], Université de Lorraine (UL)-Université de Lorraine (UL), CHU Bordeaux [Bordeaux], Exercise, Rehabilitation Sport Group (GERS), French Society of Cardiology, Centre Hospitalier Loire Vendée Océan, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)

Subjects
MESH: Health Knowledge, Attitudes, Practice, Cardiac rehabilitation, MESH: Health Care Costs, MESH: Patient Education as Topic, Exercise training, MESH: Patient Care Team, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH: Exercise Therapy, MESH: Patient Selection, ComputingMilieux_MISCELLANEOUS, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Heart Diseases, MESH: Mental Health, Société française de cardiologie, MESH: Activities of Daily Living, MESH: Adult, Therapeutic education, MESH: Cardiology, MESH: Male, MESH: France, MESH: Risk Reduction Behavior, [SDV.IB]Life Sciences [q-bio]/Bioengineering, French guidelines, MESH: Delivery of Health Care, Integrated, MESH: Female, MESH: Evidence-Based Medicine, MESH: Cost-Benefit Analysis
Abstract

International audience

Published
2012
Full Text
View/download PDF

9. Left ventricle assist device: when and which patients should we refer?

Author

Claude Girard, Jean-Noël Trochu, Richard Isnard, Pascal Leprince, Marie-Christine Iliou, Florence Beauvais, Damien Logeart, Christophe Leclercq, Jean-Pierre Gueffet, Olivier Bastien, Marie Bielefeld-Gomez, Institut du thorax, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Chirurgie cardiaque et thoracique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'anesthésie - réanimation chirurgicale [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique, pharmacologie et physiopathologie des maladies cardiovasculaires, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Systolic dysfunction, medicine.medical_treatment, Left ventricular assist device, 030204 cardiovascular system & hematology, MESH: Risk Assessment, Severity of Illness Index, Ventricular Function, Left, MESH: Ventricular Function, Left, Transplantation cardiaque, 0302 clinical medicine, Quality of life, Risk Factors, MESH: Risk Factors, 030212 general & internal medicine, Referral and Consultation, MESH: Treatment Outcome, Evidence-Based Medicine, Hypertension artérielle pulmonaire, General Medicine, 3. Good health, medicine.anatomical_structure, Treatment Outcome, Cardiology, cardiovascular system, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Cardiology and Cardiovascular Medicine, MESH: Heart-Assist Devices, MESH: Prosthesis Design, medicine.medical_specialty, Cardiac resynchronization therapy, Context (language use), Heart failure, Prosthesis Design, Risk Assessment, 03 medical and health sciences, MESH: Referral and Consultation, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, MESH: Severity of Illness Index, medicine, Humans, MESH: Patient Selection, Intensive care medicine, Insuffisance cardiaque avancée, MESH: Humans, Ventricule droit, business.industry, Patient Selection, Assistance circulatoire monoventriculaire gauche, Evidence-based medicine, medicine.disease, Transplantation, Ventricle, Ventricular assist device, MESH: Heart Failure, Heart-Assist Devices, business, MESH: Evidence-Based Medicine
Abstract

International audience; Progress in the medical treatment of patients with heart failure with systolic dysfunction, cardiac resynchronization therapy, internal cardiac defibrillators and multidisciplinary management programmes has resulted in dramatic improvements in survival and quality of life; however, this progress has led to an increase in the prevalence of advanced heart failure. In the context of organ shortage for cardiac transplantation, the technological developments in left ventricular assist devices, shown in recent positive clinical studies, provide real hope for patients with advanced heart failure. This article summarizes the most recent clinical studies concerning left ventricular assist devices and discusses for whom and when a left ventricular assist device should be proposed.

Published
2012
Full Text
View/download PDF

10. Surrogate markers predicting overall survival for lung cancer : elcwp recommendations

Author

Berghmans , T., Pasleau , F., Paesmans , M., Bonduelle , Y., Cadranel , J., Cs Toth , I., Garcia , C., Giner , V., Holbrechts , S., Lafitte , J. J., Lecomte , J., Louviaux , I., Markiewicz , E., Meert , A. P., Richez , M., Roelandts , M., Scherpereel , A., Tulippe , Ch, Van Houtte , P., Van Schil , P., Wachters , C., Westeel , V., Sculier , J. P., Renseigné , Non, Museu Nacl Hist Nat, Université de Lisbonne, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Oncology, Lung Neoplasms, medicine.medical_treatment, Medical Oncology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, MESH : Tumor Markers, Biological, Pulmonary Medicine, 030212 general & internal medicine, MESH: Treatment Outcome, MESH: Medical Oncology, MESH : Evidence-Based Medicine, Evidence-Based Medicine, Respiratory disease, MESH: Guidelines as Topic, 3. Good health, Europe, Treatment Outcome, 030220 oncology & carcinogenesis, MESH : Disease-Free Survival, Pulmonary and Respiratory Medicine, medicine.medical_specialty, MESH : Europe, MEDLINE, Guidelines as Topic, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Disease-Free Survival, 03 medical and health sciences, MESH : Medical Oncology, Internal medicine, Biomarkers, Tumor, medicine, Carcinoma, Overall survival, Humans, MESH : Lung Neoplasms, Lung cancer, MESH: Pulmonary Medicine, MESH : Guidelines as Topic, MESH : Pulmonary Medicine, MESH: Humans, MESH : Carcinoma, Non-Small-Cell Lung, business.industry, MESH : Humans, MESH: Biological Markers, Cancer, Evidence-based medicine, medicine.disease, Surgery, MESH: Lung Neoplasms, respiratory tract diseases, Radiation therapy, MESH : Biological Markers, MESH: Tumor Markers, Biological, MESH: Disease-Free Survival, MESH: Europe, Human medicine, business, Biomarkers, MESH: Carcinoma, Non-Small-Cell Lung, MESH: Evidence-Based Medicine
Abstract

International audience; The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature with experts on these questions, it can be concluded that overall survival is still the best criterion for predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if not surrogates, for survival, despite limitations in their potential application: these include time to progression, progression-free survival, objective response, local control after radiotherapy, downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer.

Published
2011
Full Text
View/download PDF

11. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper

Author

Bousquet, J, Schünemann, Hj, Zuberbier, T, Bachert, C, Baena Cagnani CE, Bousquet, Pj, Brozek, J, Canonica, Giorgio, Casale, Tb, Demoly, P, Gerth van Wijk, R, Ohta, K, Bateman, Ed, Calderon, M, Cruz, Aa, Dolen, Wk, Haughney, J, Lockey, Rf, Lötvall, J, O'Byrne, P, Spranger, O, Togias, A, Bonini, S, Boulet, Lp, Camargos, P, Carlsen, Kh, Chavannes, Nh, Delgado, L, Durham, Sr, Fokkens, Wj, Fonseca, J, Haahtela, T, Kalayci, O, Kowalski, Ml, Larenas Linnemann, D, Li, J, Mohammad, Y, Mullol, J, Naclerio, R, O'Hehir, Re, Papadopoulos, N, Passalacqua, G, Rabe, Kf, Pawankar, R, Ryan, D, Samolinski, B, Simons, Fe, Valovirta, E, Yorgancioglu, A, Yusuf, Om, Agache, I, Aït Khaled, N, Annesi Maesano, I, Beghe, B, Ben Kheder, A, Blaiss, Ms, Boakye, Da, Bouchard, J, Burney, Pg, Busse, Ww, Chan Yeung, M, Chen, Y, Chuchalin, Ag, Costa, Dj, Custovic, A, Dahl, R, Denburg, J, Douagui, H, Emuzyte, R, Grouse, L, Humbert, M, Jackson, C, Johnston, Sl, Kaliner, Ma, Keith, Pk, Kim, Yy, Klossek, Jm, Kuna, P, Le, Lt, Lemiere, C, Lipworth, B, Mahboub, B, Malo, Jl, Marshall, Gd, Mavale Manuel, S, Meltzer, Eo, Morais Almeida, M, Motala, C, Naspitz, C, Nekam, K, Niggemann, B, Nizankowska Mogilnicka, E, Okamoto, Y, Orru, Mp, Ouedraogo, S, Palkonen, S, Popov, Ta, Price, D, Rosado Pinto, J, Scadding, Gk, Sooronbaev, Tm, Stoloff, Sw, Toskala, E, van Cauwenberge, P, Vandenplas, O, van Weel, C, Viegi, G, Virchow, Jc, Wang, Dy, Wickman, M, Williams, D, Yawn, Bp, Zar, Hj, Zernotti, M, Zhong, N, In collaboration with the WHO Collaborating Center of Asthma, Rhinitis, Recherche en épidémiologie et biostatistique, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Department of Dermatology, Medical School-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Photochimie moléculaire et macromoléculaire (PMM), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), P&A Kyriakou Children's Hospital, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), inconnu, Inconnu, Forschungszentrum Jülich GmbH - Projektträger BEO, GmbH, Laboratoire d'étude des textures et application aux matériaux (LETAM), Université Paul Verlaine - Metz (UPVM)-Centre National de la Recherche Scientifique (CNRS), Merlin Circuit Technology LTD, Institute for Meteorology and Climate Research (IMK), Karlsruhe Institute of Technology (KIT), Physics Department [UNB], University of New Brunswick (UNB), Bousquet J, Schünemann HJ, R Gerth van Wijk, K Ohta, Bateman ED, M Calderon, Cruz AA, Dolen WK, Haughney J, Lockey RF, Lötvall J, P O'Byrne, Zuberbier T, O Spranger, Togias A, S Bonini, LP Boulet, P Camargos, KH Carlsen, Chavannes NH, L Delgado, SR Durham, Fokkens WJ, C Bachert, Fonseca J, Haahtela T, O Kalayci, ML Kowalski, Larenas-Linnemann D, Li J, Y Mohammad, Mullol J, R Naclerio, RE O'Hehir, Baena-Cagnani CE, N Papadopoulos, G Passalacqua, KF Rabe, R Pawankar, Ryan D, B Samolinski, Simons FE, E Valovirta, Yorgancioglu A, Yusuf OM, Bousquet PJ, je Agache, Khaled N-Aït, Annesi-Maesano I, B Begge, Kheder Ben A, MS Blaiss, DA Boakye, Bouchard J, PG Burney, WW Busse, Brozek J, M Chan-Yeung, Y Chen, AG Chuchalin, Costa DJ, Custovic A, R Dahl, Denburg J, H Douagui, R Emuzyte, L Grouse, GW Canonica, M Humbert, C Jackson, SL Johnston, MA Kaliner, Keith PK, YY Kim, JM Klossek, P Kun, la tuberculose Casale, Demoly P, AII - Amsterdam institute for Infection and Immunity, Ear, Nose and Throat, UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut de Chimie du CNRS (INC), and Internal Medicine

Subjects
Evidence-Based Medicine, Rhinitis, Allergic, Perennial, MESH: Humans, treatment, MESH: Asthma, MESH: Rhinitis, Allergic, Perennial, rhinitis, asthma, guidelines, Disease Management, Rhinitis, Allergic, Seasonal, MESH: Rhinitis, Allergic, Seasonal, Planning Techniques, MESH: Planning Techniques, MESH: Disease Management, Asthma, MESH: Practice Guidelines as Topic, Practice Guidelines as Topic, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ARIA asthma EAACI EFA GA2LEN IPCRG rhinitis nonallergic rhinitis controlled-trial severe asthma randomized-trials consort statement primary-care 2008 update recommendations management quality, MESH: Evidence-Based Medicine
Abstract

International audience; The links between asthma and rhinitis are well characterized. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines stress the importance of these links and provide guidance for their prevention and treatment. Despite effective treatments being available, too few patients receive appropriate medical care for both diseases. Most patients with rhinitis and asthma consult primary care physicians and therefore these physicians are encouraged to understand and use ARIA guidelines. Patients should also be informed about these guidelines to raise their awareness of optimal care and increase control of the two related diseases. To apply these guidelines, clinicians and patients need to understand how and why the recommendations were made. The goal of the ARIA guidelines is to provide recommendations about the best management options for most patients in most situations. These recommendations should be based on the best available evidence. Making recommendations requires the assessment of the quality of available evidence, deciding on the balance between benefits and downsides, consideration of patients' values and preferences, and, if applicable, resource implications. Guidelines must be updated as new management options become available or important new evidence emerges. Transparent reporting of guidelines facilitates understanding and acceptance, but implementation strategies need to be improved.

Published
2010
Full Text
View/download PDF

12. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

Author

Nicolas Methy, Franck Bonnetain, Laurent Bedenne, BMC, Ed., Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Centre d'épidémiologie des populations ( CEP ), and Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL )

Subjects
Oncology, Cancer Research, Time Factors, Digestive System Neoplasms, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Quality of life, Surveys and Questionnaires, Medicine, 030212 general & internal medicine, MESH: Treatment Outcome, Response rate (survey), MESH : Evidence-Based Medicine, Clinical Trials as Topic, Evidence-Based Medicine, MESH: Endpoint Determination, MESH: Research Design, MESH : Questionnaires, MESH : Research Design, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, MESH: Reproducibility of Results, medicine.anatomical_structure, Treatment Outcome, Research Design, 030220 oncology & carcinogenesis, Data Interpretation, Statistical, MESH: Survival Analysis, MESH : Disease-Free Survival, MESH : Endpoint Determination, France, MESH : Time Factors, Research Article, medicine.medical_specialty, MESH: Clinical Trials as Topic, Endpoint Determination, Rectum, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, lcsh:RC254-282, Disease-Free Survival, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Genetics, Humans, MESH : Data Interpretation, Statistical, MESH : France, Survival analysis, MESH: Humans, business.industry, Surrogate endpoint, MESH: Digestive System Neoplasms, MESH : Reproducibility of Results, MESH: Questionnaires, MESH : Humans, MESH: Time Factors, Cancer, Reproducibility of Results, MESH: Quality of Life, MESH : Quality of Life, medicine.disease, Survival Analysis, MESH : Clinical Trials as Topic, MESH: France, Localized disease, MESH: Disease-Free Survival, Quality of Life, MESH : Digestive System Neoplasms, MESH : Survival Analysis, business, MESH: Data Interpretation, Statistical, MESH: Evidence-Based Medicine
Abstract

Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL). Methods In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of cancer clinical trials. In the first questionnaire, panellists were asked to choose the most important characteristics defining a surrogate among six proposals, to give advantages and drawbacks of the surrogates, and to answer questions about their validation and use. Then they had to suggest potential surrogate endpoints for OS in each of the following tumour sites: oesophagus, stomach, liver, pancreas, biliary tract, lymphoma, colon, rectum, and anus. They finally gave their opinion on QoL as surrogate endpoint. In the second questionnaire, they had to classify the previously proposed candidate surrogates from the most (position #1) to the least relevant in their opinion. Frequency at which the endpoints were chosen as first, second or third most relevant surrogates was calculated and served as final ranking. Results Response rate was 30% (24/80) in the first round and 20% (16/80) in the second one. Participants highlighted key points concerning surrogacy. In particular, they reminded that a surrogate endpoint is expected to predict clinical benefit in a well-defined therapeutic situation. Half of them thought it was not relevant to study QoL as surrogate for OS. DFS, in the neoadjuvant settings or early stages, and PFS, in the non operable or metastatic settings, were ranked first, with a frequency of more than 69% in 20 out of 22 settings. PFS was proposed in association with QoL in metastatic primary liver and stomach cancers (both 81%). This composite endpoint was ranked second in metastatic oesophageal (69%), colorectal (56%) and anal (56%) cancers, whereas QoL alone was also suggested in most metastatic situations. Other endpoints frequently suggested were R0 resection in the neoadjuvant settings (oesophagus (69%), stomach (56%), pancreas (75%) and biliary tract (63%)) and response. An unexpected endpoint was metastatic PFS in non operable oesophageal (31%) and pancreatic (44%) cancers. Quality and results of surgical procedures like sphincter preservation were also cited as eligible surrogate endpoints in rectal (19%) and anal (50% in case of localized disease) cancers. Except for alpha-FP kinetic in hepatocellular carcinoma (13%) and CA19-9 decline (6%) in pancreas, few endpoints based on biological or tumour markers were proposed. Conclusion The overall results should help prioritise the endpoints to be statistically evaluated as surrogate for OS, so that trialists and clinicians can rely on endpoints that ensure relevant clinical benefit to the patient.

Published
2010
Full Text
View/download PDF

13. Applicability and generalisability of the results of systematic reviews to public health practice and policy: a systematic review

Author

Nizar Ahmad, Pierre Durieux, Isabelle Boutron, Philippe Ravaud, Agnès Dechartres, Centre d'épidémiologie Clinique [Hôtel-Dieu], Assistance publique - Hôpitaux de Paris (AP-HP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Hôpital Hôtel Dieu, Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Centre de médecine fondée sur les preuves, École des Hautes Études en Santé Publique [EHESP] (EHESP), Santé Publique et Informatique Médicale, This study was funded by a grant 'Recherche sur la Recherche' of the 'Délégation Interrégionale à la Recherche Clinique (DIRC), Ile de France', France., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Hôtel Dieu, and BMC, Ed.

Subjects
Male, Medicine (miscellaneous), HIV Infections, Smoking Prevention, MESH: Child, Pharmacology (medical), Child, MESH: Treatment Outcome, lcsh:R5-920, MESH: Middle Aged, Evidence-Based Medicine, Health Policy, Smoking, Health services research, MESH: HIV Infections, Middle Aged, MESH: Smoking Cessation, MESH: Review Literature as Topic, MESH: Reproducibility of Results, MESH: Health Priorities, Outcome and Process Assessment, Health Care, Treatment Outcome, Systematic review, MESH: Young Adult, Inclusion and exclusion criteria, MESH: Health Policy, Female, Health Services Research, lcsh:Medicine (General), MESH: Outcome and Process Assessment (Health Care), MESH: Health Services Research, Adult, MESH: Smoking, medicine.medical_specialty, Adolescent, MEDLINE, Context (language use), Young Adult, Environmental health, medicine, Humans, Health policy, MESH: Adolescent, MESH: Humans, Health Priorities, business.industry, Research, Public health, Reproducibility of Results, MESH: Adult, Evidence-based medicine, MESH: Male, Review Literature as Topic, MESH: Public Health Practice, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Family medicine, Public Health Practice, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Smoking Cessation, business, MESH: Female, MESH: Evidence-Based Medicine
Abstract

Background The purpose of the study was to evaluate systematic reviews of research into two public health priorities, tobacco consumption and HIV infection, in terms of the reporting of data related to the applicability of trial results (i.e., whether the results of a trial can be reasonably applied or generalized to a definable group of patients in a particular setting in routine practice, also called external validity or generalisability). Methods All systematic reviews of interventions aimed at reducing or stopping tobacco use and treating or preventing HIV infection published in the Cochrane database of systematic reviews and in journals indexed in MEDLINE between January 1997 and December 2007 were selected. We used a standardized data abstraction form to extract data related to applicability in terms of the context of the trial, (country, centres, settings), participants (recruitment, inclusion and exclusion criteria, baseline characteristics of participants such as age, sex, ethnicity, coexisting diseases or co-morbidities, and socioeconomic status), treatment (duration, intensity/dose of treatment, timing and delivery format), and the outcomes assessment from selected reviews. Results A total of 98 systematic reviews were selected (57 Cochrane reviews and 41 non-Cochrane reviews); 49 evaluated interventions aimed at reducing or stopping tobacco use and 49 treating or preventing HIV infection. The setting of the individual studies was reported in 45 (46%) of the systematic reviews, the number of centres in 21 (21%), and the country where the trial took place in 62 (63%). Inclusion and exclusion criteria of the included studies were reported in 16 (16%) and 13 (13%) of the reviews, respectively. Baseline characteristics of participants in the included studies were described in 59 (60%) of the reviews. These characteristics concerned age in about half of the reviews, sex in 46 (47%), and ethnicity in 9 (9%). Applicability of results was discussed in 13 (13%) of the systematic reviews. The reporting was better in systematic reviews by the Cochrane Collaboration than by non-Cochrane groups. Conclusions Our study highlighted the lack of consideration of applicability of results in systematic reviews of research into 2 public health priorities: tobacco consumption and HIV infection.

Published
2010
Full Text
View/download PDF

14. How to perform a critical analysis of a randomised controlled trial

Author

Candice Estellat, David J. Torgerson, Philippe Ravaud, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Department of Health Sciences, University of York [York, UK], Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Gillet, Catherine

Subjects
media_common.quotation_subject, Applied psychology, MEDLINE, Randomization, 030204 cardiovascular system & hematology, law.invention, External validity, 03 medical and health sciences, 0302 clinical medicine, Bias, Randomized controlled trial, Rheumatology, law, MESH: Rheumatology, Intervention (counseling), Medicine, Humans, 030212 general & internal medicine, Reliability (statistics), media_common, Randomized Controlled Trials as Topic, Selection bias, MESH: Humans, Evidence-Based Medicine, Sample size, business.industry, Evidence-based medicine, 3. Good health, MESH: Randomized Controlled Trials as Topic, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Data Interpretation, Statistical, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Data Interpretation, Statistical, MESH: Evidence-Based Medicine, Medical literature
Abstract

International audience; Given the large amount of medical literature of varying methodological quality, care must be taken when translating the results of randomised controlled trials into clinical practice. To assist in this translation process, we provide a method that involves answering three main questions: 'Can I trust the results?' 'How do I understand the results?' and 'To whom do the results apply?' To answer the first question, we describe important items that help in judging the reliability of the findings. For the second question, we address the clinical and statistical significance of results by looking at the size and precision of the effect. Finally, we raise the issue of external validity and of reporting adverse effects to determine which patients may best benefit from the new intervention.

Published
2009
Full Text
View/download PDF

15. Processed Meat and Colorectal Cancer: A Review of Epidemiologic and Experimental Evidence

Author

Fabrice Pierre, Raphaëlle L. Santarelli, Denis E. Corpet, Institut National de la Recherche Agronomique - INRA (FRANCE), Institut du Porc - IFIP (FRANCE), Ecole Nationale Vétérinaire de Toulouse - ENVT (FRANCE), Xénobiotiques, Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Toulouse (ENVT), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées

Subjects
MESH: Meat Products, Cancer Research, Colorectal cancer, Epidemiology, MESH: Dietary Proteins, Medicine (miscellaneous), MESH: Food Habits, Viandes transformées, Gastroenterology, MESH: Carcinogens, chemistry.chemical_compound, MESH: Nitroso Compounds, 0302 clinical medicine, MESH: Risk Factors, Risk Factors, charcuteries, salt, MESH: Animals, Food science, Nitrite, Amines, heme, NOC, Nitroso-heme, processed meat, Cancer, 0303 health sciences, MESH: Epidemiologic Studies, Nutrition and Dietetics, Evidence-Based Medicine, cancer prevention, MESH: Amines, food and beverages, 3. Good health, Meat Products, Oncology, cancer colorectal, MESH: Dietary Fats, 030220 oncology & carcinogenesis, Toxicity, Nitrosation, épidémiologie, Red meat, Salaison, Dietary Proteins, Colorectal Neoplasms, Nitroso Compounds, medicine.medical_specialty, Processed meat, review, [SDV.CAN]Life Sciences [q-bio]/Cancer, Heme, produits à base de viande, Article, 03 medical and health sciences, Internal medicine, medicine, Animals, Humans, nitrite, Carcinogen, 030304 developmental biology, MESH: Humans, Cancer prevention, business.industry, haem, cured meat, Feeding Behavior, medicine.disease, Dietary Fats, revue, Epidemiologic Studies, Charcuterie, chemistry, Carcinogens, business, MESH: Colorectal Neoplasms, MESH: Evidence-Based Medicine, Haem
Abstract

International audience; Processed meat intake may be involved in the etiology of colorectal cancer, a major cause of death in affluent countries. The epidemiologic studies published to date conclude that the excess risk in the highest category of processed meat-eaters is comprised between 20% and 50% compared with non-eaters. In addition, the excess risk per gram of intake is clearly higher than that of fresh red meat. Several hypotheses, which are mainly based on studies carried out on red meat, may explain why processed meat intake is linked to cancer risk. Those that have been tested experimentally are (i) that high-fat diets could promote carcinogenesis via insulin resistance or fecal bile acids; (ii) that cooking meat at a high temperature forms carcinogenic heterocyclic amines and polycyclic aromatic hydrocarbons; (iii) that carcinogenic N-nitroso compounds are formed in meat and endogenously; (iv) that heme iron in red meat can promote carcinogenesis because it increases cell proliferation in the mucosa, through lipoperoxidation and/or cytotoxicity of fecal water. Nitrosation might increase the toxicity of heme in cured products. Solving this puzzle is a challenge that would permit to reduce cancer load by changing the processes rather than by banning processed meat.

Published
2008
Full Text
View/download PDF

16. Effectiveness of a guideline for venous thromboembolism prophylaxis in elderly post-acute care patients: a multicenter study with systematic ultrasonographic examination

Author

Sellier, Elodie, Labarere, Jose, Bosson, Jean-Luc, Auvray, Malika, Barrellier, Marie-Therese, Le Hello, Claire, Belmin, Joel, Le Roux, Philippe, Sevestre, Marie-Antoinette, ThEMAS, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-CHU Grenoble, VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-CIC - Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Explorations Fonctionnelles [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), and VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)

Subjects
Male, medicine.medical_treatment, MESH: Lower Extremity, 030204 cardiovascular system & hematology, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Practice Guidelines as Topic, Risk Factors, MESH: Risk Factors, Acute care, Prevalence, Multicenter Studies as Topic, 030212 general & internal medicine, Prospective Studies, MESH: Heparin, Low-Molecular-Weight, Ultrasonography, MESH: Treatment Outcome, Aged, 80 and over, Venous Thrombosis, MESH: Aged, Evidence-Based Medicine, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Vitamin K antagonist, 3. Good health, Venous thrombosis, Treatment Outcome, Lower Extremity, MESH: Stockings, Compression, Practice Guidelines as Topic, MESH: Guideline Adherence, Female, Guideline Adherence, Stockings, Compression, medicine.medical_specialty, medicine.drug_class, Low molecular weight heparin, Compression stockings, MESH: Anticoagulants, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Internal Medicine, medicine, Humans, MESH: Prevalence, Aged, MESH: Humans, business.industry, Anticoagulants, Odds ratio, Guideline, Heparin, Low-Molecular-Weight, medicine.disease, Confidence interval, MESH: Prospective Studies, MESH: Male, Surgery, MESH: Venous Thrombosis, MESH: Multicenter Studies as Topic, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, MESH: Evidence-Based Medicine
Abstract

International audience; BACKGROUND: Thromboprophylaxis in elderly patients, including post-acute care patients, is at variance with scientific evidence. The purpose of this study was to determine whether a multifaceted intervention was followed by a decrease in deep venous thrombosis (DVT). METHODS: A prospective preintervention-postintervention study was conducted in 1373 patients (preintervention phase, n = 709; postintervention phase, n = 664), aged 65 years or older, enrolled in 33 hospital-based post-acute care facilities in France. An evidence-based guideline addressing pharmacologic and mechanical prophylaxis was implemented through a multifaceted intervention. The main outcome measure was any DVT diagnosed at routine comprehensive ultrasonography performed by registered angiologists. RESULTS: A DVT was found in 91 patients (12.8%) in the preintervention phase and in 52 patients (7.8%) in the postintervention phase (P = .002). The decrease in DVT involved the calf (7.1% vs 3.6%; P = .005) and the proximal venous segments (5.8% vs 4.2%; P = .18) and remained significant after adjusting for risk factors (adjusted odds ratio of any DVT, 0.58; 95% confidence interval, 0.39-0.86). Pharmacologic prophylaxis with either low-molecular-weight heparin at the high-risk dose, unfractionated heparin, and vitamin K antagonist was similar in the 2 study groups, whereas patients in the postintervention group were more likely to use graduated compression stockings (27.4% vs 34.6%; P = .004) and less likely to receive low-molecular-weight heparin at the low-risk dose (24.7% vs 18.5%; P = .006), which was not recommended by our guideline. CONCLUSIONS: A multifaceted intervention addressing venous thromboembolism prophylaxis in post-acute care patients can be followed by a significant decrease in the rate of any DVT in elderly patients. More active interventions are needed to enforce compliance with evidence-based guidelines.

Published
2006
Full Text
View/download PDF

17. ASAS/EULAR recommendations for the management of ankylosing spondylitis

Author

Zochling, J., Van Der Heijde, D., Burgos-Vargas, R., Collantes, E., Davis, J. C., Dijkmans, B., Dougados, M., Géher, P., Inman, R. D., Khan, M. A., Kvien, T. K., Leirisalo-Repo, M., Olivieri, I., Pavelka, K., Sieper, J., Stucki, G., Sturrock, R. D., Van Der Linden, S., Wendling, D., Böhm, H., Van Royen, B. J., Braun, J., Renseigné, Non, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut des Sciences de l'Evolution de Montpellier (UMR ISEM), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Montpellier (UM)-Institut de recherche pour le développement [IRD] : UR226-Centre National de la Recherche Scientifique (CNRS), Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut für Wasserbau, Universität Stuttgart [Stuttgart], CHU Cochin [AP-HP] - Assistance publique - Hôpitaux de Paris (AP-HP), Institut des Sciences de l'Evolution de Montpellier (ISEM), Université de Montpellier (UM) - Institut de recherche pour le développement [IRD] : UR226 - Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon) - Hôpital Jean Minjoz

Subjects
MESH: Antirheumatic Agents, Cost effectiveness, MESH : International Cooperation, Arthroplasty, Replacement, Hip, Cost-Benefit Analysis, International Cooperation, Delphi method, MESH : Spondylitis, Ankylosing, MESH : Arthroplasty, Replacement, Hip, Scientific evidence, 0302 clinical medicine, MESH : Exercise, MESH : Anti-Inflammatory Agents, Non-Steroidal, Immunology and Allergy, Medicine, MESH: Arthroplasty, Replacement, Hip, 030212 general & internal medicine, MESH: Treatment Outcome, MESH: Physical Therapy Modalities, MESH : Tumor Necrosis Factor-alpha, MESH : Evidence-Based Medicine, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Evidence-Based Medicine, Anti-Inflammatory Agents, Non-Steroidal, MESH: Spondylitis, Ankylosing, MESH : Antirheumatic Agents, MESH: Anti-Inflammatory Agents, Non-Steroidal, 3. Good health, Extended Report, Treatment Outcome, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Antirheumatic Agents, Number needed to treat, MESH : Cost-Benefit Analysis, Incremental cost-effectiveness ratio, medicine.medical_specialty, Evidence-based practice, Immunology, MEDLINE, MESH : Treatment Outcome, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Rheumatology, Humans, Spondylitis, Ankylosing, Exercise, Physical Therapy Modalities, 030203 arthritis & rheumatology, MESH: Humans, Tumor Necrosis Factor-alpha, business.industry, MESH : Humans, Evidence-based medicine, MESH: International Cooperation, MESH : Physical Therapy Modalities, MESH: Exercise, MESH: Tumor Necrosis Factor-alpha, Physical therapy, business, MESH: Evidence-Based Medicine, MESH: Cost-Benefit Analysis
Abstract

International audience; OBJECTIVE: To develop evidence based recommendations for the management of ankylosing spondylitis (AS) as a combined effort of the 'ASsessment in AS' international working group and the European League Against Rheumatism. METHODS: Each of the 22 participants was asked to contribute up to 15 propositions describing key clinical aspects of AS management. A Delphi process was used to select 10 final propositions. A systematic literature search was then performed to obtain scientific evidence for each proposition. Outcome data for efficacy, adverse effects, and cost effectiveness were abstracted. The effect size, relative risk, number needed to treat, and incremental cost effectiveness ratio were calculated. On the basis of the search results, 10 major recommendations for the management of AS were constructed. The strength of recommendation was assessed based on the strength of the literature evidence, risk-benefit trade-off, and clinical expertise. RESULTS: The final recommendations considered the use of non-steroidal anti-inflammatory drugs (NSAIDs) (conventional NSAIDs, coxibs, and co-prescription of gastroprotective agents), disease modifying antirheumatic drugs, treatments with biological agents, simple analgesics, local and systemic steroids, non-pharmacological treatment (including education, exercise, and physiotherapy), and surgical interventions. Three general recommendations were also included. Research evidence (categories I-IV) supported 11 interventions in the treatment of AS. Strength of recommendation varied, depending on the category of evidence and expert opinion. CONCLUSION: Ten key recommendations for the treatment of AS were developed and assessed using a combination of research based evidence and expert consensus. Regular updating will be carried out to keep abreast of new developments in the management of AS.

Published
2006
Full Text
View/download PDF

18. Combining evidence, biomedical literature and statistical dependence: new insights for functional annotation of gene sets

Author

Marc Aubry, Marie-Dominique Galibert, Anita Burgun, Marie de Tayrac, Jean Mosser, Céline Chicault, Annabelle Monnier, Institut de Génétique et Développement de Rennes (IGDR), Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Plate-forme transcriptome, Université de Rennes 1 (UR1), Modélisation Conceptuelle des Connaissances Biomédicales, Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), and Université de Rennes (UR)

Subjects
Computer science, Scientific literature, Biochemistry, Terminology, Transcriptome, MESH: Natural Language Processing, 0302 clinical medicine, Structural Biology, Profiling (information science), MESH: Proteins, MESH: Models, Genetic, lcsh:QH301-705.5, 0303 health sciences, Evidence-Based Medicine, Applied Mathematics, Methodology Article, MESH: Vocabulary, Controlled, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], Computer Science Applications, Vocabulary, Controlled, 030220 oncology & carcinogenesis, Multigene Family, lcsh:R858-859.7, DNA microarray, Algorithms, MESH: Terminology as Topic, MEDLINE, MESH: Documentation, MESH: Algorithms, Computational biology, Documentation, lcsh:Computer applications to medicine. Medical informatics, 03 medical and health sciences, Annotation, Artificial Intelligence, Terminology as Topic, Controlled vocabulary, Humans, MESH: Artificial Intelligence, MESH: MEDLINE, Molecular Biology, Gene, 030304 developmental biology, Natural Language Processing, Information retrieval, Models, Statistical, MESH: Humans, Models, Genetic, Proteins, Evidence-based medicine, lcsh:Biology (General), [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, MESH: Multigene Family, [INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM], MESH: Evidence-Based Medicine, MESH: Models, Statistical, Gene ontology annotation
Abstract

BackgroundLarge-scale genomic studies based on transcriptome technologies provide clusters of genes that need to be functionally annotated. The Gene Ontology (GO) implements a controlled vocabulary organised into three hierarchies: cellular components, molecular functions and biological processes. This terminology allows a coherent and consistent description of the knowledge about gene functions. The GO terms related to genes come primarily from semi-automatic annotations made by trained biologists (annotation based on evidence) or text-mining of the published scientific literature (literature profiling).ResultsWe report an original functional annotation method based on a combination of evidence and literature that overcomes the weaknesses and the limitations of each approach. It relies on the Gene Ontology Annotation database (GOA Human) and the PubGene biomedical literature index. We support these annotations with statistically associated GO terms and retrieve associative relations across the three GO hierarchies to emphasise the major pathways involved by a gene cluster. Both annotation methods and associative relations were quantitatively evaluated with a reference set of 7397 genes and a multi-cluster study of 14 clusters. We also validated the biological appropriateness of our hybrid method with the annotation of a single gene (cdc2) and that of a down-regulated cluster of 37 genes identified by a transcriptome study of anin vitroenterocyte differentiation model (CaCo-2 cells).ConclusionThe combination of both approaches is more informative than either separate approach: literature mining can enrich an annotation based only on evidence. Text-mining of the literature can also find valuable associated MEDLINE references that confirm the relevance of the annotation. Eventually, GO terms networks can be built with associative relations in order to highlight cooperative and competitive pathways and their connected molecular functions.

Published
2006
Full Text
View/download PDF

19. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression

Author

Bardin, Allison, Boulle, Nathalie, Lazennec, Gwendal, Vignon, Françoise, Pujol, Pascal, Endocrinologie moléculaire et cellulaire des cancers, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biologie Cellulaire et Hormonale, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, and Lazennec, Gwendal

Subjects
MESH: Aged, MESH: Angioplasty, Transluminal, Percutaneous Coronary, MESH: Humans, MESH: Practice Guidelines, MESH: Angiotensin-Converting Enzyme Inhibitors, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Coronary Arteriosclerosis, MESH: Prognosis, MESH: Male, MESH: Aged, 80 and over, [SDV.CAN] Life Sciences [q-bio]/Cancer, polycyclic compounds, MESH: T, MESH: Physician's Practice Patterns, MESH: Female, reproductive and urinary physiology, hormones, hormone substitutes, and hormone antagonists, MESH: Evidence-Based Medicine
Abstract

The characterization of estrogen receptor beta (ERbeta) brought new insight into the mechanisms underlying estrogen signaling. Estrogen induction of cell proliferation is a crucial step in carcinogenesis of gynecologic target tissues, and the mitogenic effects of estrogen in these tissues (such as breast, endometrium and ovary) are well documented both in vitro and in vivo. There is also an emerging body of evidence that colon and prostate cancer growth is influenced by estrogens. In all of these tissues, most studies have shown decreased ERbeta expression in cancer as compared with benign tumors or normal tissues, whereas ERalpha expression persists. The loss of ERbeta expression in cancer cells could reflect tumor cell dedifferentiation but may also represent a critical stage in estrogen-dependent tumor progression. Modulation of the expression of ERalpha target genes by ERbeta or ERbeta-specific gene induction could explain that ERbeta has a differential effect on proliferation as compared with ERalpha. ERbeta may exert a protective effect and thus constitute a new target for hormone therapy, such as ligand specific activation. The potential distinct roles of ERalpha and ERbeta expression in carcinogenesis, as suggested by experimental and clinical data, are discussed in this review.

Published
2004

20. Brain anatomy in Turner syndrome: evidence for impaired social and spatial-numerical networks

Author

Denis LeBihan, Arnaud Cachia, Stanislas Dehaene, Laurent D. Cohen, Nicolas Molko, Marie Bruandet, J.-F. Mangin, Denis Rivière, Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Service d'exploration de la fonction respiratoire et de médecine du sport, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire de Neuroimagerie Assistée par Ordinateur (LNAO), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Service Hospitalier Frédéric Joliot (SHFJ), Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Institut d'Informatique et de Mathématiques Appliquées de Grenoble (IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS), Service NEUROSPIN (NEUROSPIN), IFR de Neuroimagerie Fonctionnelle (IFR 49), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Neuroimagerie cognitive (LCogn), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Direction de Recherche Fondamentale (CEA) (DRF (CEA)), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay

Subjects
Adult, MESH: Turner Syndrome, Adolescent, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Cognitive Neuroscience, Numerical cognition, Spatial Behavior, Turner Syndrome, computer.software_genre, 050105 experimental psychology, MESH: Magnetic Resonance Imaging, White matter, MESH: Brain, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Voxel, MESH: Spatial Behavior, Cortex (anatomy), Image Interpretation, Computer-Assisted, medicine, Humans, 0501 psychology and cognitive sciences, Social Behavior, MESH: Adolescent, MESH: Humans, Evidence-Based Medicine, 05 social sciences, Brain, MESH: Adult, Cognition, Superior temporal sulcus, Magnetic Resonance Imaging, MESH: Cognition Disorders, medicine.anatomical_structure, MESH: Nerve Net, Female, Nerve Net, Psychology, Cognition Disorders, MESH: Image Interpretation, Computer-Assisted, MESH: Social Behavior, MESH: Female, computer, Neuroscience, MESH: Evidence-Based Medicine, 030217 neurology & neurosurgery, Diffusion MRI, Neuroanatomy
Abstract

International audience; Analysis of brain structure in Turner syndrome (TS) provides the opportunity to identify the consequences of the loss of one X chromosome on brain anatomy and to characterize the neural bases underlying the specific cognitive profile of TS subjects which includes deficits in spatial-numerical processing and social cognition. Fourteen subjects with TS and fourteen controls were investigated using voxel-based analysis of high resolution anatomical and diffusion tensor images and using sulcal morphometry. The analysis of anatomical images provided evidence for macroscopical changes in cortical regions involved in social cognition such as the left superior temporal sulcus and orbito-frontal cortex and in a region involved in spatial and numerical cognition such as the right intraparietal sulcus. Diffusion tensor images showed a displacement of the grey-white matter interface of the left and right superior temporal sulcus and revealed bilateral microstructural anomalies in the temporal white matter. The analysis of fiber orientation suggests specific alterations of fiber tracts connecting posterior to anterior temporal regions. Last, sulcal morphometry confirmed the anomalies of the left and right superior temporal sulci and of the right intraparietal sulcus. Our results thus provide converging evidence of regionally specific structural changes in TS that are highly consistent with the hallmark symptoms associated with TS.

Published
2004
Full Text
View/download PDF

21. Most psychiatrists oppose plans for new mental health act

Author

J Bindman, A J Gray, W Hopkins, P Thomas, J Moncreiff, Mike J. Crawford, Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), picoChip Designs Ltd., and Wartel, Anny

Subjects
medicine.medical_specialty, MESH: Psychiatry, media_common.quotation_subject, MESH: Attitude of Health Personnel, Mental Health Act, MESH: Forensic Psychiatry, Legislation, MESH: Patient Participation, Forensic psychiatry, Medicine, Personality, MESH: Mental Health Services, Letters, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Psychiatry, General Environmental Science, media_common, MESH: Ethics, Clinical, Government, MESH: Humans, business.industry, MESH: Questionnaires, General Engineering, General Medicine, MESH: Commitment of Mentally Ill, MESH: Research, General Earth and Planetary Sciences, MESH: Great Britain, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], business, MESH: Evidence-Based Medicine
Abstract

International audience; This paper explores service users' experiences of a 'person-centred' mental health service. We describe the development of a model of social psychiatry that places the emphasis on the experiences of the person within social and political contexts. This establishes the foundations of a 'person-centred' approach, the values of which are described briefly. The results of interviews with 20 people are presented, in which their experiences of the service are explored in detail. These interviews reveal the struggle that lies at the heart of the professional-service user dialectic, which relates to issues of institutional power, roles and responsibility, and which places professional staff in conflict with the very notion of 'person-centredness'. No matter how 'person-centred' a mental health service may strive to be, there remain serious obstacles to the full realization of this approach. Despite this critique, there were many things that were valued by those who used the service. More detailed qualitative studies are required to explicate the complex relationships and paradoxes that emerged.

Published
2001

22. Initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding nasopharynx). Part I: Locoregional extension assessment: 2012 SFORL guidelines

Author

S. Tronche, Stéphane Temam, J.-C. Ferrié, D. de Raucourt, Michel Lapeyre, C.-A. Righini, E. de Monès, Pierre-Yves Salaun, Sylvain Morinière, F. Lagarde, Sébastien Vergez, F. Dubrulle, B. Barry, Dominique Chevalier, Cécile Badoual, Chloé Bertolus, Philippe Schultz, Department of Head and Neck Surgery, Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'ORL et de Chirurgie Cervico-Faciale (TOURS - ORL et CCF), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Radiologie (LILLE - Radio), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Department of Maxillofacial Surgery, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de cancérologie cervico-faciale [Gustave Roussy] (CCF), Institut Gustave Roussy (IGR), Service d'ORL et de Chirurgie Cervico-Faciale (LILLE - ORL et CCF), Service d'ORL et de Chirurgie Cervico-Faciale (ORLEANS - ORL et CCF), Centre Hospitalier Régional d'Orléans (CHRO), Service d'ORL et de Chirurgie Cervico-Faciale (STRASBOURG - ORL et CCF), CHU Strasbourg, Service de Radiothérapie (CLERMONT FERRAND - Radiothérapie), CHU Clermont-Ferrand, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service d'ORL et de Chirurgie Cervico-Faciale (PARIS - BICHAT - ORL et CCF), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), SFORL (SFORL), SFORL, Service d'Oto-Rhino-Laryngologie (O.R.L.) et de Chirurgie Cervico-Faciale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), University Hospital Rangueil-Larrey, Service d'ORL et de Chirurgie Cervico-Faciale ( TOURS - ORL et CCF ), CHRU Tours, Service de Radiologie ( LILLE - Radio ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Service de Chirurgie Maxillo-Faciale ( PARIS - PSL - Chir Maxillo-Faciale ), Assistance publique - Hôpitaux de Paris (AP-HP), Département de cancérologie cervico-faciale [Gustave Roussy] ( CCF ), Institut Gustave Roussy ( IGR ), Service d'ORL et de Chirurgie Cervico-Faciale ( LILLE - ORL et CCF ), Service d'ORL et de Chirurgie Cervico-Faciale ( ORLEANS - ORL et CCF ), Centre Hospitalier Régional d'Orléans ( CHR ), Service d'ORL et de Chirurgie Cervico-Faciale ( STRASBOURG - ORL et CCF ), Service de Radiothérapie ( CLERMONT FERRAND - Radiothérapie ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble, Service d'ORL et de Chirurgie Cervico-Faciale ( PARIS - BICHAT - ORL et CCF ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], SFORL ( SFORL ), Service d'ORL et de Chirurgie Cervico-Faciale ( CAEN - ORL et CCF ), CHU Caen, Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF)

Subjects
Larynx, MESH : Pharyngeal Neoplasms, MESH: Lymphatic Metastasis, [SDV]Life Sciences [q-bio], MESH : Mouth Neoplasms, MESH: Laryngeal Neoplasms, MESH : Neoplasms, Multiple Primary, Oral cavity, MESH : Neoplasm Invasiveness, MESH : Narrow Band Imaging, MESH: Magnetic Resonance Imaging, Neoplasms, Multiple Primary, MESH: Mouth Neoplasms, Narrow Band Imaging, 0302 clinical medicine, Squamous cell carcinoma, MESH: Cooperative Behavior, MESH: Narrow Band Imaging, Medicine, MESH: Microscopy, Confocal, MESH: Neoplasms, Multiple Primary, MESH : Neoplasm Staging, MESH : Endoscopy, Cooperative Behavior, MESH : Carcinoma, Squamous Cell, 030223 otorhinolaryngology, MESH: Multidetector Computed Tomography, MESH : Laryngeal Neoplasms, MESH : Evidence-Based Medicine, Evidence-Based Medicine, Microscopy, Confocal, MESH : Prognosis, medicine.diagnostic_test, MESH : Lymphatic Metastasis, MESH: Carcinoma, Squamous Cell, MESH: Neoplasm Staging, MESH : Cooperative Behavior, Prognosis, Magnetic Resonance Imaging, MESH : Interdisciplinary Communication, 3. Good health, MESH: Pharyngeal Neoplasms, medicine.anatomical_structure, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Disease Progression, Mouth Neoplasms, MESH: Disease Progression, MESH: Interdisciplinary Communication, France, MESH : Multidetector Computed Tomography, medicine.medical_specialty, Tomodensitometry, MESH: Prognosis, MESH: Endoscopy, 03 medical and health sciences, MESH : Magnetic Resonance Imaging, Multidetector Computed Tomography, Carcinoma, Humans, Neoplasm Invasiveness, Basal cell, MESH : Microscopy, Confocal, MESH : France, Laryngeal Neoplasms, Neoplasm Staging, MESH: Humans, [ SDV ] Life Sciences [q-bio], business.industry, MESH : Humans, Head and neck cancer, Pharynx, Pharyngeal Neoplasms, Endoscopy, MESH : Disease Progression, Evidence-based medicine, MESH: Neoplasm Invasiveness, medicine.disease, Surgery, MESH: France, Otorhinolaryngology, Interdisciplinary Communication, business, MESH: Evidence-Based Medicine
Abstract

International audience; OBJECTIVES: To set out good practice guidelines for locoregional extension assessment of squamous cell carcinoma of the head and neck (excluding nasopharynx, nasal cavities and sinuses). MATERIALS AND METHODS: A critical multidisciplinary review of the literature on locoregional extension assessment of squamous cell carcinoma of the head and neck was conducted, applying levels of evidence in line with the French health authority's (HAS) literature analysis guide of January 2000. CONCLUSION: Based on the levels of evidence of the selected articles and on work-group consensus, graded guidelines are set out for clinical, endoscopic and imaging locoregional extension assessment of head and neck cancer.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results